# SONIA Trial and CDK4/6 Timing The **SONIA** phase 3 trial asked a practical question. Do **CDK4/6 inhibitors** need to be used in first line for everyone with **HR-positive, HER2-negative advanced breast cancer**. The main answer was no. In the overall study population, using a CDK4/6 inhibitor in first line did **not** improve **overall survival** compared with saving CDK4/6 treatment for second line. First-line use also caused more **grade 3 or higher toxic effects**. ### What SONIA tested SONIA compared two sequencing strategies: * **first-line endocrine therapy plus a CDK4/6 inhibitor**, then endocrine therapy alone in second line * **first-line endocrine therapy alone**, then endocrine therapy plus a CDK4/6 inhibitor in second line The goal was not to test whether CDK4/6 inhibitors work. That is already well established. The goal was to test whether **earlier use** improves the outcome that matters most long term. ### Main finding For the whole study population, **overall survival was not better** when the CDK4/6 inhibitor was used in first line. That matters because CDK4/6 inhibitors are often presented as an immediate default. SONIA suggests the timing can be more flexible than that. ### Why this matters in practice This does **not** mean CDK4/6 inhibitors are unhelpful. It means some patients may be able to start with **endocrine therapy alone** and keep CDK4/6 inhibition for later without clearly losing overall survival. That may be especially relevant when these issues matter a lot: * side effects * quality of life * lab and ECG monitoring burden * treatment cost * personal preference around treatment intensity ### The tradeoff The price of earlier use in SONIA was **more serious toxicity**. That matters because treatment burden is not abstract. It affects daily life, dose reductions, interruptions, and how sustainable a regimen feels over time. ### Important nuance This should not be oversimplified. A post hoc analysis suggested a possible overall-survival advantage for **first-line** CDK4/6 use in **premenopausal** patients. That means the trial supports **individualised sequencing**, not a blanket rule to delay treatment. Disease burden, pace of progression, menopausal status, prior endocrine exposure, and patient priorities still matter. ### Bottom line SONIA supports a more flexible discussion about **CDK4/6 timing**. For the overall study population, first-line use did **not** improve overall survival over second-line use, and it caused more high-grade toxicity. For some patients, that makes **endocrine therapy first, CDK4/6 later** a reasonable oncology discussion rather than an inferior fallback. ### Key References Overall survival with first-line versus second-line use of CDK4/6 inhibitors in hormone receptor-positive, ERBB2-negative advanced breast cancer: the SONIA randomized clinical trial\ PubMed entry for the SONIA overall survival analysis\ Earlier SONIA report on first-line versus second-line strategy and toxicity context\ News summary of the practical sequencing implications\ --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/cdk4-6-options-and-supplement-considerations/sonia-trial-and-cdk4-6-timing.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.